Nasus Pharma Management
Management criteria checks 2/4
Nasus Pharma's CEO is Dan Teleman, appointed in Jan 2025, has a tenure of 1.25 years. total yearly compensation is $562.16K, comprised of 42.3% salary and 57.7% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $47.59K. The average tenure of the management team and the board of directors is 7.3 years and 1 years respectively.
Key information
Dan Teleman
Chief executive officer
US$562.2k
Total compensation
| CEO salary percentage | 42.27% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 7.3yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$562k | US$238k | -US$6m |
Compensation vs Market: Dan's total compensation ($USD562.16K) is about average for companies of similar size in the US market ($USD622.00K).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan Teleman (52 yo)
Mr. Dan Teleman, MBA M.Sc., is the Chief Executive Officer at Nasus Pharma Ltd. since January 7, 2025 and serves as its Director since September 3, 2025. Mr. Teleman joined Nasus Pharma in January 2025.He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.3yrs | US$545.08k | 16.24% $ 4.3m | |
| CEO & Director | 1.3yrs | US$562.16k | 0.18% $ 47.6k | |
| Co-Founder | 7.3yrs | US$488.27k | 16.13% $ 4.2m | |
| CFO & Executive VP | less than a year | US$80.50k | no data | |
| Vice President of Administration & Human Resources | no data | no data | no data | |
| Director of CMC & Product Development | 7.3yrs | no data | 1.47% $ 384.7k |
Experienced Management: NSRX's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.3yrs | US$545.08k | 16.24% $ 4.3m | |
| CEO & Director | less than a year | US$562.16k | 0.18% $ 47.6k | |
| Co-Founder | 6.9yrs | US$488.27k | 16.13% $ 4.2m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.9yrs | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | no data | no data | no data | |
| Advisory Board Member | 1.3yrs | no data | no data |
Experienced Board: NSRX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 11:53 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nasus Pharma Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Butler | Citizens JMP Securities, LLC |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |